Datapharm Australia Pty Ltd The Australian pharmaceutical sector has seen recent innovations through PBS reform and various working groups shaping the future of the industry. Can you comment on how Datapharm is reacting to these opportunities? Datapharm has actually put in a submission to the review of the National Innovation System, highlighting that innovation…
CETIFARMA The Mexican government has been fairly pro-active about promoting good practice such as the new drug registration process that helped eliminate drugs from the Mexican market that didn’t fulfill regulatory therapeutic efficiency. In this context, what is left to do for CETIFARMA? In my opinion when the authorities take a…
Thai Pharmaceutical Manufacturers Association TPMA is the main association bringing together the local manufacturers in Thailand. What do you consider to have been the main milestones and achievements since your inception? We haven’t reached any milestones yet. Our first milestone will be to open and free the pharmaceutical market in Thailand by breaking the…
Astellas Pharma Ltd. South Africa The South African affiliate was established in June 2003. Could you come back on the main milestones in the company’s development from 2003 onwards? Yamanouchi as an entity was an agency in South Africa under Pharmaplan from 1996. In 1997 I joined Pharmaplan as the Managing Director and ran the…
HLB Pharma Group Your entry into the Argentinean pharmaceutical market in 2004 was very unconventional, with your ‘holistic solution’ that had not been seen before in Argentina. Why was the time right in 2004 to start HLB Pharma? Hernán López Bernabó: We saw a special moment in Argentina to start a new company…
Bayer Schering Pharma Argentina The Bayer Schering merger in 2006 saw you add Argentina and Bolivia to your existing responsibilities as General Manager of Schering for Paraguay and Uruguay. What have been some of the challenges you have faced since that time? Argentina is a challenging market, and the system is very complex. This…
Pharma Dynamics In 2005, when Focus Reports interviewed you, you were more towards the start up phase of Pharma Dynamics; and you have significantly grown in the market since then. What new dimension has Pharma Dynamics today in the South African pharma market, and how have you integrated the company’s growth in…
Janssen Pharmaceutical Hungary Hungary is one of the largest pharmaceutical markets in the region, and has been used by Janssen-Cilag as a hub. Can you elaborate on how important Hungary is for Janssen-Cilag within the CEE region today? It is not the easiest question, as Hungary’s importance is changing from year to year.…
GSK Pharma CIS GSK CEO Andrew Witty has said that GSK must move away from selling “white pills in Western markets” in order to offset widespread generic erosion. This means diversifying the company’s portfolio into novel areas and putting greater emphasis on emerging markets. How is the Russian affiliate contributing to the realization…
Pharmstandard You have lead this company since its beginnings in 2003, when it acquired ICN pharmaceuticals. In 2007, Pharmstandard carried out an IPO of 43% of its shares. How has the company developed since the IPO? We were honored on the London Stock Exchange as the Best Newcomer of 2007, and…
Ferring Pharmaceuticals SA Representative Office in Romania Ferring is a company with a tremendous history dating back to the 1950s in Sweden. Now present in over 50 countries, the Group has managed to maintain a double digit annual growth over the last 2 decades. Focusing on Romania in particular, can you first of all tell us more…
Biopharmaceutical investments of RVC (RVC BioFund) Biofund is an independent spin-off of the broader Russian Venture Capital organization. What is the working relationship and synergy between these agencies, and what are the market conditions that have necessitated the creation of Biofund? Biofund was created on January 24th, 2011. There are two stakeholders in the creation of…
See our Cookie Privacy Policy Here
